Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

ITEM5.03

On January5, 2017, Sangamo BioSciences, Inc. (the Company)
changed its corporate name to Sangamo Therapeutics, Inc. by
filing the Third Certificate of Amendment of the Companys Seventh
Amended and Restated Certificate of Incorporation (the
Certificate of Amendment) with the Secretary of State of the
State of Delaware (the Name Change). The amendment was effected
to Section242 of the Delaware General Corporation Law, which
permits such amendments to be adopted by a corporations Board of
Directors without stockholder approval; the Name Change was
approved by the Companys Board of Directors on December5, 2016.

The Name Change does not affect the rights of the Companys
security holders and the Companys common stock will continue to
trade on The NASDAQ Global Market under the symbol SGMO.

The foregoing description of the Certificate of Amendment is
qualified in its entirety by reference to the full text of the
Certificate of Amendment, a copy of which is filed as Exhibit 3.1
and incorporated by reference herein.

On January6, 2017, Sangamo Therapeutics, Inc. issued a press
release announcing the Name Change, a copy of which is attached
as Exhibit 99.1 hereto and is incorporated herein by reference.

About Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics. Its ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It has preclinical programs in hemophilia A and Lysergic acid diethylamide and research stage programs in monogenic diseases, including certain central nervous system disorders and cancer immunotherapy.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Recent Trading Information

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) closed its last trading session up +0.20 at 3.65 with 1,491,536 shares trading hands.